20/20 Biolabs, Inc. AIDX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -1.79% | -- | 31.75% | 30.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -1.79% | -- | 31.75% | 30.30% |
| Cost of Revenue | -- | -6.67% | -- | 6.54% | 14.56% |
| Gross Profit | -- | 14.15% | -- | 175.37% | 113.84% |
| SG&A Expenses | -- | -12.88% | -- | -29.68% | -0.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -17.05% | -- | -22.35% | -1.05% |
| Operating Income | -- | 22.59% | -- | 36.82% | 10.09% |
| Income Before Tax | -- | -0.93% | -- | 34.78% | 7.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -0.93% | -- | 34.78% | 7.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -0.93% | -- | 34.78% | 7.45% |
| EBIT | -- | 22.59% | -- | 36.82% | 10.09% |
| EBITDA | -- | 22.24% | -- | 36.97% | 9.76% |
| EPS Basic | -- | 17.69% | -- | 35.44% | 8.38% |
| Normalized Basic EPS | -- | 16.78% | -- | 35.74% | 8.70% |
| EPS Diluted | -- | 17.75% | -- | 35.56% | 8.17% |
| Normalized Diluted EPS | -- | 16.78% | -- | 35.74% | 8.70% |
| Average Basic Shares Outstanding | -- | 17.18% | -- | 1.16% | 1.01% |
| Average Diluted Shares Outstanding | -- | 17.18% | -- | 1.16% | 1.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |